The emergence of antibiotic resistance in a wide variety of important pathogens of humans presents a worldwide threat to public health. This paper describes recent work on the use of mathematical models of the emergence and spread of resistance bacteria, on scales ranging from within the patient, in hospitals and within communities of people. Model development starts within the treated patient, and pharmacokinetic and pharmacodynamic principles are melded within a framework that mirrors the interaction between bacterial population growth, drug treatment and the immunological responses targeted at the pathogen. The model helps identify areas in which more precise information is needed, particularly in the context of how drugs in£uence pathogen birth and death rates (pharmacodynamics). The next area addressed is the spread of multiply drug-resistant bacteria in hospital settings. Models of the transmission dynamics of the pathogen provide a framework for assessing the relative merits of di¡erent forms of intervention, and provide criteria for control or eradication. The model is applied to the spread of vancomycin-resistant enterococci in an intensive care setting. This model framework is generalized to consider the spread of resistant organisms between hospitals. The model framework allows for heterogeneity in hospital size and highlights the importance of large hospitals in the maintenance of resistant organisms within a de¢ned country. The spread of methicillin resistant Staphylococcus aureus (MRSA) in England and Wales provides a template for model construction and analysis. The ¢nal section addresses the emergence and spread of resistant organisms in communities of people and the dependence on the intensity of selection as measured by the volume or rate of drug use. Model output is ¢tted to data for Finland and Iceland and conclusions drawn concerning the key factors determining the rate of spread and decay once drug pressure is relaxed.
INTRODUCTION
Genetic diversity is a characteristic of microbes, whether their lifestyle is free-living or parasitic. The last few years has seen rapid advances in our understanding of the genetic diversity within bacterial populations and the structures of the genetic codes of a series of important species, including some major pathogens of humans such as Mycobacterium tuberculosis (Cole et al. 1998) . One aspect of this genetic diversity and the potential for rapid evolution within bacteria that is of major public health signi¢-cance worldwide is the emergence and spread of antibiotic resistance in a wide variety of organisms that infect humans, and birds plus mammal species within the agricultural industry. Today many view the evolution and spread of antibiotic resistance as the major public health crisis of the late part of this century, with the evolution of bacteria within hospital settings that are resistant to all major antibiotics a distinct possibility in the very near future.
The study of antibiotic resistance is a ¢eld that has largely been the preserve of the microbiologist and the infectious disease clinician responsible for the care of patients with bacterial infections. Until recently, most have had con¢dence in the pharmaceutical industry to keep one step ahead of the microbe in terms of producing new antibiotics that can combat infection by organisms resistant to the previous generations of drugs. To date that has certainly been the case. However, the rate of discovery of new compounds has slowed considerably over the past three decades, in part due to the very high costs of research, development and testing prior to the successful launch of a new antibiotic. In discussions of how best to combat resistance or how to slow its spread, the debates have largely centred on the microbiological and clinical issues. Very few papers in this important ¢eld address the key population genetic issues that underpin an understanding of the evolution and spread of resistant organisms (Bjo« rkmann et al. 1998; Stilianakis et al. 1998; Blower et al. 1998; Levin et al. 1997; Austin et al. 1997a,b; Bonhoe¡er et al. 1997; Schrag et al. 1997; Lenski 1997; Lenski et al. 1994; Massad et al. 1993 ). An even smaller number attempt to meld current understanding of the transmission dynamics of bacteria in human communities (including hospitals), with the key population genetic factors Bonhoe¡er et al. 1997) . The number of publications that meld these two areas, in combination with an understanding of the mechanisms of the evolution of resistance, patterns of drug consumption and the pharmacokinetics and pharmacodynamics of de¢ned drugs and pathogens, can be counted on one hand Austin et al. 1998b) .
The general issue is that an interdisciplinary approach is needed to interpret correctly current patterns of evolution and spread, plus address the issue of how best to manage antibiotic resistance in both the healthcare and community settings. Techniques and concepts from a wide variety of di¡erent ¢elds must be harnessed, such as those in pharmacology, microbiology, population genetics and epidemiology. A powerful template to merge the methods and concepts of these di¡erent ¢elds of scienti¢c study can be constructed by the sensible use of simple and complex mathematical models of the key biological processes. The case for the use of a mathematical framework is made even more compelling by the strong existing traditions for the use of mathematical methods in the ¢elds of pharmacology, population genetics and epidemiology.
In this paper we present some recent research that melds di¡erent components of these various ¢elds to address problems at a series of di¡erent levels of study. These include the evolution of resistance within the treated host, the spread of resistance within and between hospital settings, and the epidemiology and evolution of resistance in communities of people. Our approach is the use of simple mathematical templates and our aim is to shed light on the key factors that control observed patterns of antibiotic resistance and how drug use can be tailored to slow the likelihood of evolution and rapid spread. A central problem in management is the key principle that the stronger the selective pressure, the more rapid will be the pace of evolution to meet this pressure. The frequency of antibiotic resistant organisms in a de¢ned population of bacteria is invariably related to past or current patterns of drug use. To alter frequency it is necessary to change the direction of selection. How best to do this will depend on the precise details of host, bacteria and drug. However, a precise mathematical template for study helps identify what needs to be measured and the key processes determining observed pattern.
WITHIN-HOST MODELS OF INFECTION AND ANTIBIOTIC TREATMENT
The use of mathematical models for the analysis of viral infections such as HIV has resulted in considerable advances in our understanding of both disease progression and the impact of drug therapy (Ho et al. 1995; Wei et al. 1995; Bonhoe¡er et al. 1996; Austin et al. 1998b ). In the case of bacterial infections, where within-host dynamics is not so easily measurable, there have been fewer advances ). In the pharmacological research literature, mathematical models of drug absorption and elimination kinetics have been widely used. This ¢eld of study is referred to as pharmacokinetics (Rowland & Tozer 1995; Austin et al. 1998b) . A large amount of data are available on the pharmacokinetics of antibiotic agents which can be usefully employed in mathematical models of bacterial infection and treatment. The e¡ect of an antibiotic on the target pathogen usually correlates with the concentration of the drug in the habitat of the pathogens. The study of dynamical response of the infectious agent in the presence of the drug is termed pharmacodynamics (Lo« wdin et al. 1998; Aeschlimann et al. 1998; Berg et al. 1996; Hyatt et al. 1995; Drusano et al. 1993) and provides the link between pharmacokinetics and models of within host pathogen population dynamics (Austin et al. 1998b) .
(a) Pharmacokinetics and pharmacodynamics
Antibiotics may be administered either orally, intramuscularly or intravenously, and the eventual concentration of active drug at the site of infection will be determined by the dose, the route of administration and the dosage regimen. Dosage regimens are designed to maintain drug concentrations at therapeutic levels, and must balance issues of both toxicity and e¤cacy (Rowland & Tozer 1995) . For simplicity, we concentrate on changes in the concentration, C(t), of a single antibiotic given at a dose, D, to a host with volume of distribution V such that C 0 D/V, where C 0 is the initial concentration. If absorption is rapid (i.e. can be ignored) or the antibiotic is given intravenously, and elimination follows ¢rst-order kinetics (as is common during the early stages of elimination), then the plasma concentration at time t is determined by
where k is the elimination constant and the half-life of the drug is t 1a2 ln (2)/k. Assuming doses are given at discrete times t 0, t (, t 2(, etc. then the concentration immediately after i doses will be
where r exp(À k() is the decay factor. After several doses the regimen reaches equilibrium and the concentration C(t) lies between the limits rC max 4C(t)4C max where C max C 0 and 1a(1 À r) is called the accumulation factor. Typically, the impact of a drug in a de¢ned pathogen population saturates with increasing drug concentration. Suggested reasons for this saturation include metabolic e¡ects such as enzyme production and a ¢xed number of sites where a drug can act on the invading organism. We use the so-called E max saturating model, where if E is the e¡ect of the drug (e.g. per capita death rate of the bacteria due to the action of the drug at concentration C), then
Hence, E max denotes the maximum e¡ect, C 50 the concentration at half e¡ect and n is a shape factor denoting the slope of the curve.
Many of the pharmacodynamic studies of antibiotic e¡ect involve growth curves, in which an organism is grown in varying concentrations of drug either in vitro or in vivo (Lo« wdin et al. 1998; Aeschlimann et al. 1998; Berg et al. 1996; Hyatt et al. 1995) . In order to model these growth curves we require a mathematical model of the population growth of bacteria. If !(N) is the net growth rate of a bacteria if N organisms are present (allowing for density dependence) and (C) the bacterial kill rate at drug concentration C, then in the absence of any post antibiotic e¡ect,
For in vitro studies !(N) !N(1 À NaK) where K is a carrying capacity determined by the experiment. This simple model can be used to ¢t experimental data providing a concentration^kill rate pharmacodynamic curve (¢gure 1). In this dynamical model a minimum inhibitory concentration (MIC) can be de¢ned as the concentration which just inhibits bacterial growth i.e. (C) !, or equivalently,
where E !a is the ratio of maximum kill rate to net growth rate. For bacteriostatic antibiotics (e.g. macrolides) the net growth rate becomes a function of drug concentration, !(C), however the conclusions from our analyses will remain unchanged. The e¡ects of antibiotic resistance will manifest themselves via the pharmacodynamics of antibiotic action. Conventional measures of antibiotic resistance take the form of MIC determination and categorization via breakpoints. An increased MIC may be a result of any combination of three factors determined by the form of equation (6) . First, C 50 may increase, thereby shifting the overall curve to the right in a linear manner. Second, E may decrease thereby reducing the peak bactericidal kill rate, . Third, the shape function, n may increase (although this e¡ect will be minimal). Since pharmacodynamic studies have thus far tended to focus on sensitive organisms, the precise pharmacodynamic e¡ects of antibiotic resistance remain uncertain (¢gure 2). It is, however, important that these e¡ects be quanti¢ed, as they have profound in£uences on the usefulness of a drug. For example, if C 50 increases then the saturating bactericidal kill rate can still be reached (for a su¤ciently high dose, D), hence clinical improvement may be seen by doubling the dose of amoxicillin for infections with reduced sensitivity (as proposed in Spain). If, however, bactericidal activity is reduced, then no increase in dose will ever be able to compensate for the loss of sensitivity and the clinical lifetime of the drug cannot be increased. Typical mechanisms for antibiotic resistance may include e¥ux whereby the drug is pumped out of the cell (e.g. Pseudomonas aeruginosa resistance to imipenem (Livermore 1992) ), altered target site (e.g. penicillin-binding protein) and deactivation of the drug by enzymes (e.g. beta-lactamase resistance) (see Salyers & Whitt (1994) for further details). For drug e¥ux the ¢rst pharmacodynamic e¡ect would appear most likely, the drug is at a reduced concentration within the cell. Where the target site is altered, increasing concentration will obviously have little e¡ect. When a drug is broken down by enzyme activity, increasing the number of sites can restore sensitivity, as has been demonstrated by the use of clavulanic acid added to amoxicillin (Nahwani & Wood 1993) .
(b) Mathematical models of antibiotic therapy
Pharmacodynamic models provides the ideal template for constructing models of antibiotic therapy and the emergence of resistance. Once the concentration^kill rate curve is known, equation (5) can be solved under given assumptions, such as exponential growth of the bacteria in the absence of a drug, multiple dosing, multiple strains and the in£uence of acquired immunity. We use the complete E max model throughout and begin by considering the e¡ects of multiple dosing during exponential growth . Dividing equation (5) by N, gives the simpli¢ed form
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Phil. Trans. R. Soc. Lond. B (1999) Figure 1 . In vitro pharmacodynamic e¡ect of imipenem killing of Pseudomonas aeruginosa at concentrations of 0, 4 and 64 mg l À1 . Data are shown from Berg et al. (1996) . Parameters used are ! 1X6 h À1 , N(0) 10 5 , K 3X2 Â 10 9 CFU (colony forming unit), 4 h À1 , C 50 3 mg l À1 , n 1X2. Imipenem is eliminated from the system with constant k 0X054 h À1 . Figure 2 . Concentration^kill rate curve for imipenem killing of Pseudomonas aeruginosa, with MIC for sensitive (MIC 2 mg l À1 ) and resistant strains showing the e¡ects of (i) increased C 50 (MIC =10 times sensitive value), and (ii) reduced saturating kill rate, . Pharamacodynamic parameters are as ¢gure 1. Increased C 50 resistance implies that increasing the dose can always give therapeutic concentrations (toxicity issues aside).
which has the general solution
If treatment occurs at discrete times (as in the multiple dosing regimen), then the change in ln N,
Therapeutic regimens require that D ln N i 40 (as an absolute minimum), which gives a threshold concentration C 0 5C min for a given decay parameter, r exp(À k(),
depending on dose i. For the ¢rst dose
and at equilibrium (i 3 I) C min (I) C min (0)a. For example, suppose an antibiotic is given every half-life ( 2) and E 0X5 (i.e. MIC C 50 ) and n 1. For the ¢rst dose C min (0) MIC 2 p for therapeutic bene¢t, whereas once equilibrium is reached C min (I) MICa 2 p . Figure 3 shows the e¡ect of multiple dosing on the pharmacodynamics of imipenem acting against Pseudomonas aeruginosa (MIC 1mg l À1 and 10 mg l À1 ). Elimination of the antibiotic reduces the kill rate from a peak (determined by both the dose and the MIC), and dosing returns the kill rate back up the curve. Since the concentration is plotted on a log scale and elimination is assumed to be ¢rst order (i.e. exponential), the length of the curve is proportional to time. Therapeutic regimens must keep the kill rate, (C), above the net growth rate, !, of the bacterium, which is shown for the sensitive strain (MIC 1mg l À1 ). The resistant strain (MIC 10 mg l À1 ) will however show net growth because the dose (and hence C 0 D/V) is below the minimum required for therapeutic activity, C min .
(i) Dose splitting: the e¡ect of multiple dosing Dosage regimens are typically expressed in the form C ( q(, i.e. a concentration C ( given every time period (. 500 mg of penicillin given every 6 h (500q6) could equally be administered as 250 mg every 3 h (250q3). We write this as aC ( qa( where a41. If a regimen is subdivided into 1/a subdoses at intervals ( H ( /a then the total log reduction in bacteria, D ln N(a) is given by
Summing individual terms using equation (9) gives a total log reduction
For ¢xed total drug, C 0 , and constant pharmacodynamics, in the limit as ( becomes large and r becomes small,
In other words, bacterial abundance in the patient is reduced as a increases. The implications for antibiotic therapy are that splitting a dose can maximize therapeutic e¡ect, depending on pharmacodynamic parameters. This has been demonstrated numerically , but equation (14) provides a clearer understanding of the phenomenon.
(ii) The in£uence of acquired immunity
The assumption of exponential population growth is only valid if density-dependent e¡ects such as competition for resources and e¡ect or immune responses are not acting within the host. Acquired immunity means that most community-acquired infections are self-limiting, although morbidity may be considerable depending on the degree to which immunological responses can control pathogen growth. For example, in the absence of resistant strains, if I(t) is the measure of the severity of immunological responses directed at the pathogen (i.e. speci¢c T or B cells) at time t and 1/" is the average duration of the immune response (i.e. e¡ector cell life expectancy), then growth) then the exact solution of these equations is possible:
where I 0 L 0 /" is the maximum immune response and x I 0 /! is the ratio of immune killing to net bacterial growth rate. If x41 then the immune response can control the infection and the bacteria reach a maximum population at a time
depending on the persistence of the immune response, 1/". If bacterial growth is logistic, i.e. !(N) !(1 À K/N) clearance is also possible provided x41. Where the immune response proliferates in response to the total bacterial population we assume a saturating response of the form
where a is the maximum per capita proliferation rate, b is the bacterial population which gives half the maximum rate and 0 determines the form of proliferation (0 0,1 with saturation when 0 1). Where resistant strains are also present N N s N r . If some ¢tness cost is associated with resistance (e.g. reduced growth rate, ! H 4!), the full model takes the form
Numerical evaluation of these equations (¢gure 4) shows that for self-limiting infections the overall immune response, I(t), will be determined by both the degree of resistance (measured by MIC r ) and the time elapsed before treatment begins. For example, early treatment will reduce the total bacterial population, N (i.e. morbidity), and, in doing so, the resulting immune response (thereby increasing susceptibility to subsequent infections). The reduction in immunity, which is what clears highly resistant strains, will also produce a proportionately more resistant infection (albeit with reduced morbidity), which may have transmission consequences for other hosts. These consequences will be discussed in greater detail in ½ 5.
TRANSMISSION DYNAMICS OF ANTIBIOTIC RESISTANT PATHOGENS IN HOSPITALS
The continued evolution of antibiotic resistance in common hospital pathogens presents an ever-increasing threat to public health. Organisms once considered of low invasive potential now give cause for concern in immunocompromised hosts. The recent emergence of vancomycinresistant enterococci (VRE) as a nosocomial pathogen is a striking example of this new danger to vulnerable patients. Treatment options are often limited to combining antimicrobials or experimental compounds of unproven e¤cacy. Other pathogens, such as Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), have also developed multiple resistance and give even greater cause for concern. Reports of MRSA strains with reduced susceptibility to vancomycin (Hiramatsu et al. 1997; Tabaqchali 1997) , suggest that unless there is a return to conventional practices of infection control, with its emphasis on reduced transmission, antibiotic therapy may not be possible in the near future for some hospital acquired infections.
Many factors contribute to make hospitals a favourable environment for the development of resistance, not least of which is the broad spectrum of antimicrobials used to treat infection (Tenover & McGowan 1996) . Another important factor is the frequent mixing of patients and health-care workers (HCWs)öfor whom asymptomatic carriage is a potential threat. Although some emphasis has been placed on the population dynamics of competition between resistant and susceptible bacteria (Massad et al. 1993; Bonhoe¡er et al. 1997) , little work has been completed to date with regards to the transmission dynamics of resistant infections within frameworks that meld genetics and epidemiology (Austin et al. 1998a; Sebille et al. 1997) . Many hospital pathogens are capable of colonizing patients without inducing overt symptomatic infection. This generated the belief that new hospital outbreaks were a consequence of endogenous activation from patient sources or environmental contamination. However studies of both VRE and fungal pathogens have demonstrated that indirect transmission via the hands of transiently contaminated HCWs is a very important determinant of colonization and infection (Sanchez et al. 1992; Bonten et al. 1996) . 
4 , N r (0) 2 and I(0) I 0 .
ward or intensive-care unit (ICU). The number of HCWs is assumed to be ¢xed (N h ), and HCWs are also assumed to be either uncolonized (X h ) or transiently colonized (Y h ). The transmission dynamics can be described by four ordinary di¡erential equations (¢gure 5):
where L is the patient admission rate, 0 the prevalence of colonization at admission, D p 1/" the average patient's length of stay (LOS) (typically days), c is the HCWp atient contact rate, b h and b p the respective probabilities of transmission from patient3HCW and HCW3patient, and D h 1/ the average duration of transient colonization (typically hours).
Optimal use of available resources frequently requires that available beds be always occupied (i.e. X p Y p N p L/"). Under this assumption the respective colonization prevalences for patients ( y p (t) Y p (t)/N p ) and HCWs ( y h (t) Y h (t)/N h ) are determined by the two di¡erential equations:
where R h b h cN p D h and R p mb p cN p D p are the respective HCW^patient and patient^HCW reproductive numbers, and m N p /N h is the sta¡^patient ratio (typically 1:1 for ICUs and less for general wards). Because transmission is via patient^HCW^patient, the overall reproductive number for transmission, R 0 , takes the composite form
The endemic prevalences are given by
(¢gure 6). If new admissions are carefully screened and colonized patients isolated from the ward (i.e. 0 0), the closed system reduces to the Ross^Macdonald model for malaria transmission (Anderson & May 1991) , with vector^host ratio m and biting rate a cN p . The endemic solution takes the simple symmetrical form
Where there is a considerable separation in time-scales (as in this instance), there will be a large di¡erence in endemic prevalences. Typically R p ) 1 and R h ( 1, only the product R 0 R p R h must be greater than unity for transmission. Therefore in endemic settings the model predicts that y Ã p ) y Ã h , providing one explanation of the observational ¢nding that culturing the hands of HCWs seldom provides pathogen isolates (Morris et al. 1995) .
(i) Hand-washing
Hand-washing by HCWs between patient contacts reduces the probability b p that they will transmit the pathogen to their next patient. If p is the e¤cacy of handwashing protocols (equal to the compliance rate times the e¤cacy/wash), then R 0 (p) (1 À p)R 0 . Transmission can be curtailed (and colonization eradicated) provided R 0 (p)51, i.e. if p exceeds the threshold rate p c 1 À 1aR 0 and new admissions are screened (0 0). Even if washing hands is 100% e¡ective, the threshold compliance rate can be very high for modest values of R 0 . Studies show reported compliance rates of 20^40% (Albert & Condie 1981; Simmons et al. 1990; Doebbelling et al. 1992) . If R 0 is in excess of 1.25^1.67, hand-washing measures alone are unlikely to be su¤cient for controlling endemic transmission. (
ii) Management of HCWs
Introducing more HCWs into a ward can either reduce or increase transmission levels, depending upon the management of the ward. Where HCW resources are limited, increasing the number of HCWs will increase transmission due to an increased number of contacts between HCWs and patients. Conversely in the ICU, where resources are less limited, increasing the numbers of HCWs reduces transmission because individual sta¡ workloads are reduced. Cohorting HCWs on a 1:1 basis can provide a very e¡ective method of limiting transmission. If q is the conditional probability that a HCW returns to the same patient rather than visiting another patient, then the e¡ective HCW^patient ratio m(q) m(1 À q). Using the same argument as above, there is a threshold cohorting rate q c 1 À 1aR 0 . E¡ective measurement of cohorting rates have yet to be reported. However given that 1:1 HCW^patient ratios are not unusual in ICU settings, cohorting rates are likely to exceed those of hand-washing providing a possible focus for resource allocation (¢gure 7).
(b) Stochastic considerations
Since the number of HCWs and patients is typically small (less than 30) in most hospital settings, stochastic £uctuations will play an important role in determining the course of an outbreak. When modelling any single outbreak a full stochastic realization of equations (24)^ (27) is required (Renshaw 1991; Anderson & May 1991) (¢gure 8a). Where there is a signi¢cant separation of time-scales and the number of patients remains constant, the quasi-steady state (QSS) approximation (dY h /dt 9 0) can be used to reduce equations (24)^(27) to
An explicit closed solution of this equation is only possible in the limit R h y p 3 0, which is the logistic equation with immigration of new infectives (Appendix A). In the absence of colonized admissions (0 0) the quasiequilibrium probability distribution % i , that i patients will be endemically colonized, can be calculated (¢gure 8b). Smaller wards and ICUs with few beds will have large £uctuations in prevalence. For example, if R 0 2 and N p 9 beds, the predicted 95% con¢dence region for y Ã p is y Ã p 9 38X9 AE 46X27. The magnitude of £uctuations when patient numbers are small implies that identifying trends in endemic settings, perhaps induced by changes in management practices, will be very di¤cult.
(c) The emergence of resistance
The previous theoretical framework of indirect transmission is equally applicable to both antibiotic-sensitive and -resistant pathogens. However, it does not take into account any measure of the selection pressure exherted by antibiotic treatment. When more than one bacterial strain is present the framework must be modi¢ed accordingly to re£ect all available therapy combinations. For analytical simplicity we retain the QSS approximation and take the limit R h 3 0 in the closed model of equation (34).
Within an ICU, the majority of patients will receive an antibiotic, either as prophylaxis (e.g. digestive decontamination) or for the treatment of overt infection (e.g. vancomycin for staphylococcal wound infections). Antibiotic therapy may select for resistance by either of two mechanisms. First, treatment may induce or select preexisting resistant organisms within a host (so-called acquired resistance). Second, by killing o¡ the existing host £ora, antibiotic treatment increases the susceptibility to colonization by resistant bacteria. Patients who become colonized with resistant £ora may then develop overt infection and subsequently have an increased LOS, which in turn increases opportunities for further transmission. Earlier work on antibiotic management has focused on the e¡ects of treatment on reducing durations of infection, as might be expected for upper respiratorytract infection (Massad et al. 1993; Bonhoe¡er et al. 1997) . We use a similar framework to focus on the e¡ects in ICU settings.
(i) Single drug therapy
We begin by considering the case when only a single antibiotic (or class of antibiotics if resistance patterns are common) is in use. Using the QSS approximation and assuming that all admitted patients are uncolonized (0 0), the prevalence of colonization for sensitive ( y p ) and resistant ( y H p ) strains are determined by the equations
where a is the proportion of patient stay for which antibiotics are administered, ' the probability of acquired resistance during treatment and primes denote parameters for the resistant strain. Switching parameters, let y denote the prevalence of colonization ( y y p y H p ) and f the frequency of resistance ( f y
where D" " À " H 50. If transmission is una¡ected by antibiotic treatment (e.g. infection control practices limit the spread of both strains), df /dt can be solved exactly. If f 0 is the frequency of resistance at time t 0 , f is determined by the logistic solution,
The parameter E measures the selective pressure of acquired resistance (since there is no di¡erence in transmission) and is determined by E a'(1 1/q), where q is the percentage increase in LOS for resistantly colonized patients (q (D H p À D p )aD p ). In the limit ' 0 (no acquired resistance), if f 0 40 then f 3 1 and resistance will tend to ¢xation at a rate independent of antibiotic treatment. This is simply a consequence of resistantly colonized patients remaining in the ICU longer and therefore having a higher reproductive number (R H 0 4R 0 ). The characteristic time-scale for the ecological replacement of sensitive colonization is of order 1aD", irrespective of antibiotic consumption. Where antibiotic treatment induces acquired resistance and no resistance is present at time t 0 , the time for resistance to reach 507 of cases, T 50 is given by
Typically if D 7 days, q 257 (D H 1X25D), a 807 of patient stay and ' 107, then E 0X04 and D" 0X0286 week
71
, giving T 50 48 days. Halving antibiotic consumption increases T 50 to 59 days, demonstrating that ecological replacement of sensitive colonization is playing a dominant role.
The selective transmission advantage antibioticresistant strains have is likely to play a considerable role in the overall emergence of resistance. If LOS is una¡ected by antibiotic treatment (i.e. D" 9 0) and acquired resistance minimal (' 0), then
where the reproductive number for resistant strains is una¡ected by antibiotic treatment. For sensitive strains, antibiotic treatment reduces the probability of acquisition,
. Therefore R 0 (a) (1 À aq)R 0 and resistant strains will have a selective advantage provided R H 0 5R 0 (a) or equivalently;
Once this threshold is breached, resistance will increase logistically until ¢xation. If y(0) 1 À 1/R 0 (a) is the initial endemic prevalence of colonization, and f 0 9 1/N p (one resistant patient) then
As an example, if R H 0 R 0 (0) in the absence of antibiotic therapy, then equation (42) is always satis¢ed and resistant strains will always have a selective advantage. Therefore, R H 0 À R 0 (a) aqR 0 , implying that if antibiotic consumption is halved then the time to reach 50% resistance (T 50 ) will double.
(ii) Multiple drug policies Introducing a second antibiotic (or class of antibiotics) provides a greater scope for the management of the evolution of drug resistance. Sensitive infections can be treated with a choice of drug, but more importantly patients with resistant organisms can also be treated e¡ectively. If two drugs are in use then four possible resistance patterns are possible, sensitive ( y p ), resistant to drug 1 ( y H p ), resistant to drug 2 ( y HH p ) and resistant to both drugs ( y HHH p ). Increasing the number of antibiotics gives a maximum of 2 N resistance patterns for N drugs used. Retaining the constant population size and QSS approximations, the model for two antibiotics takes the form (1 À a 1 ). The precise in£uence on R 0 (a 1 ,a 2 ) depends on how the drug is used. If a single drug treatment is used then R 0 (a 1 ,a 2 ) R 0 (1À a 1 À a 2 ) with a 1 a 2 41. If, however, multiple antibiotics are used a 1 a 2 may be greater than unity and we take the maximal form R 0 (a 1 ,a 2 ) R 0 (1 À max(a 1 ,a 2 )). Figure 9 shows examples of intervention drug use strategies. Sequential drug use, whilst retaining the second antibiotic solely for resistant infections provides a good method of retaining overall e¤cacy at the risk of multiple resistance. This policy is, however, determined by the rate of acquired resistance for each drug, the relative LOS for resistant patients and whether multiply resistant patients can be e¡ectively isolated. The e¡ective-ness of rotating antibiotics at regular intervals depends on the period of rotation; too frequent and resistance has no time to decline, too infrequent and resistance may reach endemic levels. It has been argued that the most e¤cient policy is to use multiple therapy for all patients (Bonhoe¡er et al. 1997) . This has the advantage that the risk of acquired resistance will be much lower (since singly resistant strains are removed and multiple resistance unlikely). However, this brings complications of cost and possible side e¡ects. Provided multiply resistant patients can be e¡ectively isolated (i.e. R HHH 0 9 0, e.g. by removal from the ICU), careful management of resistance is possible using both interventionist (e.g. cycling) and non-interventionist (e.g. combination) policies.
EPIDEMIC SPREAD OF HOSPITAL OUTBREAKS OF MRSA AND VRE (a) Transmission model
The rapid dissemination of multiply resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) presents new challenges to the treatment of hospital-acquired infection. In England and Wales the number of hospitals a¡ected by epidemic MRSA has increased from 40 per month in 1993 to more than 100 per month in 1997 (PHLS 1997). In New York City the transmission of VRE between hospitals led to 38 out of 81 hospitals reporting VRE outbreaks within three years (Frieden et al. 1993) . The recent emergence of VRE in hospitals in the UK is of particular concern since vancomycin use is restricted to the treatment of MRSA and other multiply resistant infections. Nevertheless, epidemic strains of VRE were ¢rst detected in the UK in 1987, and as recently as 1995, were detected in 47 hospitals (including 27 for the ¢rst time) (PHLS 1996) .
In many instances hospital outbreaks have proved both expensive (in associated costs) and di¤cult to eradicate, requiring careful surveillance and e¡ective infection control measures (Cookson 1995; Boyce et al. 1995; Cox & Conquest 1997) . Each case of MRSA in England and Wales was estimated to carry an additional cost of »2500 in increased patient stay and additional antimicrobial treatment (Mehtar 1995) . The longer an outbreak persists, the greater the likelihood that it may spread between wards and eventually to other una¡ected hospitals or into the community. Reductions in the duration of outbreaks and the transfer of colonized or infected patients are therefore of the utmost importance during the early stages of an epidemic, where greatest impact can be achieved.
Since epidemiological data on hospital outbreaks of VRE and MRSA are presently only available at a hospital level (rather than number of patients a¡ected), we begin with an epidemiological framework in which hospitals are classi¢ed as either una¡ected (susceptible) or having a con¢rmed outbreak (infectious). In the immediate period post-outbreak, a hospital may be on increased alert and less susceptible to subsequent outbreaks (recovered^immune), although such e¡ects are likely to be small. Outbreaks arise as a consequence of either de novo spontaneous introduction, perhaps from a background source such as a nursing home or the community, at a per capita rate ', or by the transfer of colonized patients and sta¡ between institutions. Once con¢rmed, an outbreak persists for an average duration D days, with eradication rate 1aD. We assume that the total number of hospitals remains constant for the duration of the epidemic. If n(t) denotes the number of a¡ected hospitals at time, t, and N is the total number of hospitals, then n(t) is determined by the di¡erential equation
The transmission parameter, , incorporates the prevalence of colonization in the source hospital, the transfer rate between hospitals and the probability of establishing an outbreak in the una¡ected hospital. Equation (48) is the closed SIS model with immigration of infectives (see Appendix A) and can be rewritten in terms of two new parameters; growth rate, r N À ( ') and carrying capacity, K ra,
Data suggest that spontaneous outbreaks are rare for MRSA (PHLS 1997; , and we take the limiting approximation ' 3 0, to obtain the well-known logistic solution
It is helpful to make the transformation from ecological parameters, r and K, to epidemiological parameters, R 0 and D, where R 0 ND is the number of secondary outbreaks generated by the ¢rst primary outbreak, such that R 0 Na(N À K) and rD Ka(N À K).
Once an epidemic has begun to take o¡, stochastic £uctuations during the exponential phase are not very important. However, as the number of a¡ected hospitals approaches the endemic state (n Ã K) £uctuations away from the endemic state become signi¢cant, and it is important to evaluate their magnitude (Appendix A).
Surveillance programmes and infection control practices can reduce both the transmission parameter , and outbreak duration D. Fractional changes in these key parameters give corresponding changes in growth rate and carrying capacity such that,
Reductions in either transmission parameter or outbreak duration will therefore be equally e¡ective in the longterm reduction in carrying capacity. However, reductions in transmission produce greater short-term reductions in growth rate and lower incidences of new outbreaks.
(b) EMRSA-15 in England and Wales
Epidemic strains of MRSA are colonizing hospital patients throughout England and Wales (PHLS 1997) (¢gure 10a). Strain EMRSA-15 has become widely disseminated and now accounts for over 100 a¡ected hospitals per month. Assuming de novo introductions are infrequent (' 9 0), maximum-likelihood techniques can be used to estimate the three unknown parameters; r, K and n 0 n(1993). Assuming a total of N 400 hospitals are at risk, the log likelihood, l is given by
where n i is the number of reported outbreaks at time t i and i is summed over all available data points. Maximizing l(r,K,n 0 ) gives r 1X08 yr 71 (95% CI 0.94^1.20), K 158 hospitals (95% CI 143^173) and n(1993) 13X2 (95% CI 10.8^15.6) hospitals (1 2 42X34, # 48 d.f., P G( 
(c) Model re¢nements (i) Hospital size
Heterogeneity in hospital size and organization may have considerable in£uence on the transmission dynamics. Subdividing hospitals by size, let N k denote the total number of hospitals with k beds (k may denote a subclass) and n k the number with outbreaks. Then N k N k and the number of hospitals with k beds reporting outbreaks will be
where ! k l kl h l is the force of infection and kl the transmission parameter from a hospital with l beds to one with k beds. Assuming that ! k scales with size (i.e. ! k k! or equivalently kl klahki) whilst outbreak duration D remains constant, at endemic equilibrium ! satis¢es (Anderson & May 1991) 
The reproductive number R 0 (k) is obtained in the limit ! 3 0, hence
The reproductive number can be signi¢cantly greater than the mean behaviour if the standard deviation ' 2 k hk 2 i À hki 2 is much greater than the mean hki. Socalled`superspreading hospitals' can therefore play a disproportionate role. For England and Wales hospitals are graded by NHS trust size (data not shown), rather than number of beds and are accurately described by a truncated normal distribution of the form
where p(x) is the probability a hospital will have x beds, " 432X5 and ' 410X7. The corresponding mean available beds per trust is " x 542X7 with variance ' (ii) Spatial spread
The simple model of hospital^hospital transmission can be adapted spatially via either multiple patches (e.g. regional health authorities) (Lloyd & May 1996) or random di¡usion (Shigesada & Kawasaki 1997) . Let n(x,t) denote the density of a¡ected hospitals at time t and coordinate x (x, y). The random di¡usion model of epidemic spread in two dimensions is expressed as
where D is the di¡usion coe¤cient. Exact solution of this equation is not possible, although approximation of the exponentially growing phase with ' 0 gives the radial solution
at time t and distance & from the primary outbreak. The distribution at any given time is Gaussian, although the density increases exponentially at large time-scales. A wave of outbreaks will propagate from the primary hospital with limiting velocity
Our estimates of the growth rate for EMRSA-15 suggest that c 9 2X1 D p . Once more detailed information becomes available about the spatial spread of various EMRSA strains, theory may provide possible explanations of why di¡erent strains have had very di¡erent epidemic patterns, and how the present epidemic of VRE might spread throughout England and Wales.
ANTIBIOTIC RESISTANCE IN THE COMMUNITY
Although hospitals are rightly viewed as so-called`hot zones' where selection of multiply resistant strains is most common, the bulk of antibiotic consumption occurs in the community. As already demonstrated, the primary selection pressure driving changes in the frequency of resistance is the volume of drug use. Establishing a precise quantitative relationship between antibiotic consumption and the frequency of resistance in community settings has been di¤cult due to the lack of longitudinal studies that record both resistance and consumption patterns (Nissinen et al. 1995; Arason et al. 1996; Seppa« la« et al. 1997) . In a study by Nissinen et al. (1995) in Finland following the rapid emergence of -lactamase resistance in Moraxella catarrhalis, increasing -lactam consumption led to further increases in the frequency of -lactamase producing clinical isolates. Many bacterial species, such as Escherichia coli, Haemophilus in£uenzae, Neisseria meningitidis, Moraxella catarrhalis, Streptococcus pneumoniae and Staphylococcus aureus, exist as commensals in their human hosts with asymptomatic colonization. Arason et al. (1996) considered how the rates of carriage and resistance of S. pneumoniae in children in day-care centres were linked to antimicrobial consumption. Reductions in selection pressure will lead to reductions in resistance, although the time-scales may be considerable. In Finland, reducing macrolide consumption appears to have led to reductions in the frequency of macrolide resistance in S. pyogenes (Seppa« la« et al. 1997) . Each of the studies has measured both antibiotic resistance and selection pressure, providing an opportunity to characterize the relationship between carriage, consumption and resistance.
(a) A model of bacterial carriage and antibiotic consumption
Few theoretical frameworks have examined the coupling between population genetics, transmission dynamics and antibiotic consumption (Austin et al. 1997 Levin et al. 1997) . We begin by proposing a simple mathematical framework in which a population of human hosts experience colonization by a directly transmitted commensal organism (such as S. pneumoniae or H. in£uenzae). Antibiotic treatment is assumed to be prescribed independently of colonization in response to overt infection by other strains or species that induce morbidity. In the absence of`resistant' strains (where resistance will be more clearly de¢ned later), hosts fall into one of four classes; untreated-uncolonized (x), treated-uncolonized (X), untreated-colonized ( y) and treated-colonized (Y) (¢gure 11). The prevalence of each of these classes is determined by the di¡erential equations;
where is the prescribing rate (per unit time), 1a the average length of treatment (typically days) and ' the probability that treatment does not clear colonization.
The transmission dynamics of colonization are determined by , the rate commensals are spread to other hosts, 0 the protection a¡orded by treatment and 1a! the average duration of colonization (typically months). Demographics are described by L, the per capita birthî mmigration rate and 1a" the average duration hosts remain in the community. For children in day-care centres or the elderly in nursing homes 1a" may be comparable with 1a!. For analytical simplicity we assume that the number of hosts is ¢xed (i.e. L "), hence x y X Y 1 at all times. The basic reproductive number is given by R 0 a! H , where ! H ! ". In the absence of antibiotic therapy, a commensal can cause an epidemic with probability 1 À 1aR 0 and will become established with endemic prevalence p y Ã 1 À 1aR 0 .
(i) Antibiotic consumption
Consumption of antibiotics is conventionally measured in de¢ned daily doses per 1000 adults (DDDs/1000), equivalent to the proportion of the community, a X Y, receiving treatment at any time. For adults, the equivalence is good and a 9 0X5^17; however, for children, where doses depend on age and consumption is much greater (a 9 57), the equivalence is poor . For a constant population size, a is determined by
Since typical treatment times are short compared to colonization ( ) !), a rapidly reaches the equilibrium value a 9 a or equivalently; prescribing rate multiplied by length of treatment. The simple assumptions about the nature of antibiotic treatment lead to two endemic extremes, depending on non-clearance rate, ', and reduced susceptibility, 0.
(ii) Antibiotic treatment clears and prevents colonization
Where commensals are fully susceptible to antibiotics, treatment may both clear and prophylactically protect against colonization completely (0 ' 0). Increasing antibiotic consumption will therefore reduce the average duration of colonization and the number of hosts who are susceptible. The prophylactic properties of treatment imply that the endemic state is given by
where (" )a(" !) is the ratio of length of colonization to length of treatment (typically ) 1). Eradication of a commensal from a population is possible provided y Ã 40, or equivalently a5a c ( p) where p is the prevalence without treatment ( p 1 À 1aR 0 ), and the threshold consumption is given by
For example, when 50% of hosts are colonized and 4, a threshold a c 157 of hosts must be treated at any time (¢gure 12). Since a is typically much less than 100% and large, to O(a),
giving a c 1a6 for the previous estimate.
(c) Antibiotic treatment has no e¡ect on colonization Should antibiotic treatment leave colonization unchanged (0 ' 1) (which may be the case where a commensal is fully resistant or an antibiotic has very high speci¢city and does not reach the colonization site), there is an absolute separation between consumption and carriage such that and their contribution to transmission can in most instances be ignored. The true e¡ect of antibiotic treatment is likely to lie between these two extremes. When a new antibiotic is ¢rst introduced, ' 9 0, implying that treatment will have a considerable e¡ect on carriage. As the frequency of resistance increases so too will ', eventually tending to unity when resistance is complete. To incorporate the e¡ects of resistance three possibilities can be considered. First, a mean minimum inhibitory concentration (MIC) can be de¢ned over the whole population. The clearance failure rate must evidently be a function of MIC; low MICs will lead to clearance, high MIC non-clearance. Resistance is classically determined by break points, with the broad distinctions; (S)ensitive, (I)ntermediate or (R)esistant being made. Second, using microsimulation techniques, a population-genetic approach can be used to model the e¡ects of individual hosts. Competing selection takes place within colonized hosts, and the relative ¢tness of sensitive and resistant strains will be determined by whether individual hosts are receiving treatment . Finally additional resistant classes can be added to the original framework to include untreated-resistant and treated-resistant colonized hosts (Austin et al. 1997b) .
(b) Non-clearance as a function of MIC
We have already seen how the MIC plays an important role in determining the within-host outcome of antibiotic therapy. Where doses maintain antibiotic concentrations above MIC for su¤cient periods, clearance of bacteria will result. For commensal organisms, which may colonize other areas of the body aside from the pathogen of interest, the MIC antibiotic concentration may be di¡erent but the underlying criterion remains. The rate of non-clearance is therefore a function of mean MIC (i.e. '(m)). Since antibiotic activity is well described by the E max model, the non-clearance rate will also be determined by a saturating function of the form
where m 50 is the MIC at which only 50% of colonization is cleared and n is a constant determined by the underlying within host pharmacodynamics. If a partial di¡erential equation approach is taken, x, y, X and Y become functions of both time and MIC, such that equations (61)^(64) are replaced by equations of the form
where parameters , ! , ' and 0 become functions of m. The mean MIC is given by .
The system of equations exhibits limiting behaviour when m ( m 50 and m ) m 50 , i.e. ' 9 mam 50 and ' 9 1, respectively. Immediately after an antibiotic has been introduced y(0) y Ã (a) (equation (68)) and any densitydependent e¡ects on MIC increase will be small. If 
Communities with higher colonization rates or antibiotic consumption, will see faster emergence of strains with elevated MICs. Once MICs are above m 50 non-clearance becomes much more frequent. It is here that densitydependent e¡ects may be more clearly felt. Where there is no e¡ect, m(t) increases linearly with time. When p (m) decreases monotonically, an eventual upper bound is placed on m.
Numerical solutions with parameter estimates typical of penicillin-resistant Streptococcus pneumoniae (PRP); R 0 2, 1a! 2 months (Christenson et al. 1997) , 1 yr
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, 1a 5 days (a 1X47), m 50 1 mg ml À1 , p (m) 1 mg ml À1 give a doubling time of approximately two years (¢gure 13). Exact calculation of p (m) requires detailed longitudinal MIC data which has yet to be made available. Resistant strains of S. pneumoniae are characterized by MIC in excess of 1 mg ml À1 , suggesting that if m0 m 50 a100, PRP carriage will become a problem after 10^20 years of relatively intense selection.
(c) Explicit resistant classes
A second way of incorporating resistance is via the introduction of an explicit second commensal strain, which is assumed to either be resistant or at the very least have reduced susceptibility (Austin et al. 1997 (Austin et al. , 1999a . A further two classes of host are required: untreatedresistant (z) and treated-resistant (Z). Since antibiotic treatment is assumed to either clear sensitive strains or induce acquired resistance (with probability '), the class that is treated-sensitive (Y) is redundant. Resistance is again assumed to be associated with some ¢tness cost, although the precise nature of this cost is in the form of reduced transmission success (measured by R H 0 ). Recalling that the reproductive number is the product of transmission rate and duration of carriage, resistant strains may manifest themselves either via reduced transmissibility (lower ) or increased duration of carriage (higher !), or both. A further measure of transmission success is captured in the role of superinfection, i.e. the net probability that a host colonized with a resistant strain will revert to sensitive following contact with other sensitively colonized hosts. Under these assumptions, the two-strain model with antibiotic prescribing takes the form
where z Z and primes denote parameters for resistant commensal strains. In the absence of resistance endemic colonization is again given by equation (68), with the threshold for eradication a c , unchanged.
(i) Relationship between antibiotic consumption and resistance
Using the simplifying assumption that antibiotic consumption is low (a ( 1), an approximate solution of the model is possible (Appendix B). If non-clearance rates are zero, two thresholds are de¢ned; a for emergence of resistance, and a y for the eradication of sensitive commensal (equivalent to a c ). Coexistence requires only that a 4a4a y . Where there is no transmission ¢tness cost (R H 0 R 0 ), a y 0a c and a a y a(1 0) (¢gure 14). The endemic frequency of resistance, f Ã (a), is related to antibiotic consumption by the relationship
Changes in antibiotic consumption, Da, will give corresponding changes in resistance, Df 
with limits Daaa (a y À a)aa y for the ¢xation of resistance and Daaa (a À a)aa for its eradication. Small changes in antibiotic consumption can therefore induce considerable changes in resistance if consumption is su¤-ciently close to either of the thresholds, a or a y .
(ii) Emergence of -lactamase resistance in Moraxella catarrhalis in Finland
Since 1977 M. catarrhalis resistance to -lactams has increased rapidly in Europe and the USA reaching 808 5% (Berk et al. 1996) . Studies in Finland using clinical isolates from otitis media in children aged less than six years show a rapid rise in resistance from 0% (n 53) in 1978 to 57% (n 115) in 1983. During this time -lactam antibiotic consumption was estimated to have remained roughly constant at 5.5 DDDs/1000 adults (a 0X557) (Nissinen et al. 1995) . After the introduction of second generation cephalosporins there followed a further 51% increase in -lactam consumption and an associated rise in -lactam resistance (¢gure 15). Parameter estimation is done by minimizing a weighted least squares estimate using multidimensional direction set methods (Press et al. 1992) and numerical realizations of the equations (79)^(83). The approximate solution gives excellent agreement where selection pressure is constant (1978^1985).
Parameter estimates give a 3X87 or equivalently 38 DDDs/1000 children, which is in keeping with other estimates of infant antibiotic consumption (Arason et al. 1996) . It should be stressed that the parameters are for children less than six years old and that evidently antibiotic consumption in children di¡ers widely from that of the whole community. This non-equivalence presents an important gap in our knowledge. Since children are the largest consumers of antibiotics, conventional measures of consumption fail to estimate the true selection pressure in those with the highest rates of carriage. There is an interplay between transmission success (R 
DISCUSSION
The series of problems discussed in this paper are broad, ranging from MIC levels within a treated patient to the community-based frequency of drug resistance. In each case mathematical models provide insights into the interpretation of observed pattern and the management of antibiotic resistance. The various models discussed re£ect di¡ering degrees of sophistication in terms of the overall goal of melding approaches from pharmacology, microbiology, population genetics and epidemiology. By concentrating ¢rst on the within-host dynamics of treatment and expanding into population-based epidemiological models, it is possible to see how the the treatment of the individual has implications for the wider population.
Our analyses demonstrate clearly the widely di¡ering proximity of theory with experiment and observation. In some cases, such as the spread and management of antibiotic resistance in an intensive care setting, estimates for the values of key parameters and variables are often available. In other areas, such as the pharmacodynamics of the interaction between speci¢c drugs and speci¢c bacteria, data are sparse (particularly so for resistant organisms). It is surprising that the level of quanti¢cation is so high for the pharmacokinetic side, yet so sparse for the pharmacodynamics. Models should help to stress how important such measurements are to the evaluation and management of antibiotic resistance. Speci¢cally, where one or more drugs are used to treat a particular bacterial infection, the design of treatment protocols to minimize the likelihood of the emergence of resistance requires much more precise pharmacodynamic data.
More generally, there are also important gaps in quanti¢cation and measurement in the population genetic and epidemiological areas. It again seems surprising that so few studies have provided precise longitudinal data on the frequency of resistance in a well-de¢ned sample of the patient population, and concomittently, the volume of drug consumption over time in that population. The latter is the strength of selection and its precise measurement is key to the interpretation of how the frequency of resistance changes over time. Related to this issue is the question of sampling. In general, too little thought has been given to date on how best to monitor temporal changes in the frequency of resistance to a particular drug in de¢ned organisms. There is an urgent need for concerted action internationally in this area, given the globally mixing nature of the world's population today and the speed with which antibiotic resistance can spread from one country to another.
Once data are available, the use of mathematical models provides a quantitative tool for possible scenario analysis. An obvious example is the epidemiological spread of multiply resistant bacteria between hospitals. Once the key parameters have been estimated, questions regarding the impact of intervention strategies (such as surveillance and outbreak control) can be addressed in a meaningful way. Understanding the dynamics of the model provides additional information regarding implementation time-scales. For example, theory demonstates Figure 15 . Prediction of a two-step rise in the frequency of b-lactamase producing isolates of Moraxella catarrhalis (Nissinen et al. 1995) . Initial colonization is assumed to be endemic with (0) 0X002 and a 37X7 DDDs/1000 children (4%). All other parameters are as in ¢gure 15. The approximate solution (Appendix B) is in good agreement with the numerical results prior to the introduction of cephalosporins in 1986.
